<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00765700</url>
  </required_header>
  <id_info>
    <org_study_id>TDLP-110-101</org_study_id>
    <nct_id>NCT00765700</nct_id>
  </id_info>
  <brief_title>Ketoprofen 10% Cream for Treatment of Pain Associated With Mild to Moderate Acute Soft Tissue Injury</brief_title>
  <official_title>A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study to Assess the Efficacy and Safety of Ketotransdel™ (Ketoprofen Topical Cream 10%) in the Treatment of Pain Associated With Mild to Moderate Acute Soft Tissue Injury.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imprimis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cato Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Imprimis Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Imprimis Pharmaceuticals is investigating a proprietary, topical cream formulation consisting&#xD;
      of 10% ketoprofen (containing 100 mg of ketoprofen in 1gram of cream) for the local treatment&#xD;
      of acute musculoskeletal pain.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to determine the efficacy and safety of ketoprofen 10%&#xD;
      cream compared to placebo as a three-times-per-day topical application in improving the&#xD;
      patient assessment of pain when used to treat mild to moderate acute soft tissue injury of&#xD;
      the upper and lower extremities over a 7-day period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the efficacy of ketoprofen 10% cream in subjects with acute pain associated with mild to moderate acute soft tissue injury (acute sprain or strain) of upper and lower extremities on the day 3 visit.</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the safety, tolerability and other parameters of ketoprofen 10% cream in subjects with acute pain associated with mild to moderate acute soft tissue injury of upper and lower extremities.</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>To assess the pharmacokinetics of ketoprofen after 7 days of topical application</measure>
    <time_frame>8 days</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">364</enrollment>
  <condition>Sprain</condition>
  <condition>Strain</condition>
  <condition>Acute Soft Tissue Injury</condition>
  <arm_group>
    <arm_group_label>Ketoprofen 10% Cream</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Topical Ketoprofen 10% Cream&#xD;
1gram three times daily for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Topical placebo cream&#xD;
1gram three times daily for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical Ketoprofen 10% Cream</intervention_name>
    <description>Topical Administration</description>
    <arm_group_label>Ketoprofen 10% Cream</arm_group_label>
    <other_name>Ketotransdel (TDLP-110)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical Placebo Cream</intervention_name>
    <description>Topical Administration</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
    <other_name>Vehicle</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 to 70 years of age&#xD;
&#xD;
          -  Have a diagnosis of uncomplicated acute soft tissue injury of the upper or lower&#xD;
             extremity that has occurred within the 72 hours preceding the baseline visit.&#xD;
&#xD;
          -  The injury site must be accessible to the patient so that he or she can apply the&#xD;
             study treatment himself or herself.&#xD;
&#xD;
          -  Meet pain entry criteria.&#xD;
&#xD;
          -  Willing to discontinue use of any pain medication or treatments not provided as part&#xD;
             of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Grade 3 sprain or strain, bilateral sprain or strain, or concomitant fracture or open&#xD;
             wound at the site of the sprain or strain, or have a serious injury, as determined by&#xD;
             the investigator (e.g., nerve damage, joint instability, or tendon rupture).&#xD;
&#xD;
          -  Previous injury to the same area within 3 months prior to current injury.&#xD;
&#xD;
          -  Active skin lesions or disease at the intended site of application of the study&#xD;
             medication. Skin lesions include open wounds, rash, papules, vesicles, and erythema&#xD;
             associated with the site of injury.&#xD;
&#xD;
          -  Pharmacologic treatment (NSAIDs or analgesic medications) for the injury less than 12&#xD;
             hours before the baseline assessments.&#xD;
&#xD;
          -  Any form of opioid use since the time of injury.&#xD;
&#xD;
          -  Any form of steroid use within 30 days prior to study entry.&#xD;
&#xD;
          -  Non-pharmacologic treatments of the injury other than rest, ice, compression, and/or&#xD;
             elevation (RICE) prior to the baseline visit.&#xD;
&#xD;
          -  History or physical examination finding that is not compatible with safe participation&#xD;
             in the study as determined by the study doctor, such as gastrointestinal (stomach,&#xD;
             intestine) ulcer or bleeding within 6 months documented by an upper-gastrointestinal&#xD;
             series (UGI x-ray, barium meal) or endoscopy (GI scope), anemia or abnormal bleeding,&#xD;
             moderate to severe kidney disease, or moderate to severe liver disease.&#xD;
&#xD;
          -  A history of, or evidence for, underlying disease in the injured area, such as&#xD;
             osteoarthritis or gout.&#xD;
&#xD;
          -  Clinically significant, poorly controlled lung, stomach, liver, kidney, heart, or&#xD;
             other vital organ disease as determined by the study doctor or nurse.&#xD;
&#xD;
          -  A history of allergy to ketoprofen or ketoprofen-containing products.&#xD;
&#xD;
          -  A history of allergy to soy lecithin or soy lecithin-containing products.&#xD;
&#xD;
          -  Medications (drugs) or other substances contraindicated due to the nature of study&#xD;
             medication that include:&#xD;
&#xD;
               -  Allergies to prescription or over-the-counter products containing acetaminophen&#xD;
                  (e.g., Tylenol®), which is used as rescue medication&#xD;
&#xD;
               -  History of aspirin-sensitive asthma, or aspirin-associated rhinitis or nasal&#xD;
                  polyps&#xD;
&#xD;
               -  Taking warfarin, parenteral heparin, ticlopidine or clopidogrel&#xD;
&#xD;
               -  Taking lithium or methotrexate&#xD;
&#xD;
               -  Taking probenecid or similar drugs that might affect the kidneys&#xD;
&#xD;
          -  Received an investigational drug or product or participated in an investigational drug&#xD;
             study within a period of 30 days prior to receiving study medication.&#xD;
&#xD;
          -  Scheduled elective surgery or other invasive procedures during the period of study&#xD;
             participation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Illana Katsnelson, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cato Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CATO Research</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>E. Ekman, S. Skrepnik, M. Jones , K. Lawson, and J. Schupp. EFFICACY AND SAFETY OF KETOPROFEN 10% CREAM IN ACUTE SOFT TISSUE INJURIES (PHASE 3 STUDY TDLP-110-001). Poster Presentation, Sep. 2, 2010, 13th World Congress on Pain in Montreal, Canada.</citation>
  </results_reference>
  <verification_date>September 2013</verification_date>
  <study_first_submitted>October 1, 2008</study_first_submitted>
  <study_first_submitted_qc>October 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2008</study_first_posted>
  <disposition_first_submitted>September 17, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>September 20, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 27, 2013</disposition_first_posted>
  <last_update_submitted>September 20, 2013</last_update_submitted>
  <last_update_submitted_qc>September 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 27, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sprain</keyword>
  <keyword>Strain</keyword>
  <keyword>Pain</keyword>
  <keyword>Ankle Pain</keyword>
  <keyword>Shoulder Pain</keyword>
  <keyword>Elbow Pain</keyword>
  <keyword>Tennis Elbow</keyword>
  <keyword>Knee pain</keyword>
  <keyword>Wrist Pain</keyword>
  <keyword>Hand Pain</keyword>
  <keyword>Muscle, Bone and Cartilage Disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Soft Tissue Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketoprofen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

